Table 1.
Pathological features and engraftment rates of RCC cases in this study
| Case | Sex | Age | Pathologic stage | Nodal and metastatic stage | Furhman grade | Additional pathologic features | TSG generation and engraftment rate (engrafted/total) | Comments |
|---|---|---|---|---|---|---|---|---|
| 1 | M | 42 | T3a | NxMx | III | First, 55% (12/22) | VHL mutation1 | |
| 2 | F | 59 | T3a | NxM1 (bone and brain) | IV | Rhabdoid | First, 72% (21/29) | Cytoreductive nephrectomy after neoadjuvant sunitinib2 |
| 3 | F | 64 | T3a | NxMx | III | Sixth3, 83% (10/12) | Postoperative metastases4 |
1
The patient has a known mutation of the Von-Hippel-Lindau (VHL) gene that is validated in this study.
2
The patient presented with metastatic disease at time of diagnosis and underwent brain and bone metastasectomy, followed by two cycles of neoadjuvant sunitinib before cytoreductive nephrectomy and the implantation of the primary tumor tissue into mice. The patient developed liver metastases within a year after surgery.
3
Tumor tissues from this patient were serially passaged in mice and the tumor graft line used in this study was the sixth generation of TSG.
4
Postoperative development of new lung and pancreatic metastases within 6 months after surgery.